Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure: Design and rationale of the BioMEMS study

Aims Heart failure (HF), a global pandemic affecting millions of individuals, calls for adequate predictive guidance for improved therapy. Congestion, a key factor in HF‐related hospitalizations, further underscores the need for timely interventions. Proactive monitoring of intracardiac pressures, g...

Full description

Saved in:
Bibliographic Details
Published in:European journal of heart failure 2024-08, Vol.26 (8), p.1736-1744
Main Authors: Allach, Youssra, Barry‐Loncq de Jong, Mylene, Clephas, Pascal R.D., Gent, Marco W.F., Brunner‐La Rocca, Hans‐Peter, Szymanski, Mariusz K., Halm, Vokko P., Handoko, M. Louis, Kok, Wouter E.M., Asselbergs, Folkert W., Kimmenade, Roland R.J., Manintveld, Olivier C., Mieghem, Nicolas M.D.A., Beeres, Saskia L.M.A., Rienstra, Michiel, Post, Marco C., Heerebeek, Loek, Borleffs, C. Jan Willem, Tukkie, Raymond, Mosterd, Arend, Linssen, Gerard C.M., Spee, Ruud F., Emans, Mireille E., Smilde, Tom D.J., Ramshorst, Jan, Kirchhof, Charles J.H.J., Feenema‐Aardema, Margriet W., Fonseca, Carlos A., Heuvel, Mieke, Hazeleger, Ronald, Eck, J.W. Martijn, Boersma, Eric, Kardys, Isabella, Boer, Rudolf A., Brugts, Jasper J.
Format: Article
Language:English
Subjects:
Biomarkers
Haemodynamic monitoring
Heart failure
Intracardiac pressures
Repeated measurements
Risk stratification
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims Heart failure (HF), a global pandemic affecting millions of individuals, calls for adequate predictive guidance for improved therapy. Congestion, a key factor in HF‐related hospitalizations, further underscores the need for timely interventions. Proactive monitoring of intracardiac pressures, guided by pulmonary artery (PA) pressure, offers opportunities for efficient early‐stage intervention, since haemodynamic congestion precedes clinical symptoms. Methods The BioMEMS study, a substudy of the MONITOR‐HF trial, proposes a multifaceted approach integrating blood biobank data with traditional and novel HF parameters. Two additional blood samples from 340 active participants in the MONITOR‐HF trial were collected at baseline, 3‐, 6‐, and 12‐month visits and stored for the BioMEMS biobank. The main aims are to identify the relationship between temporal biomarker patterns and PA pressures derived from the CardioMEMS‐HF system, and to identify the biomarker profile(s) associated with the risk of HF events and cardiovascular death. Conclusion Since the prognostic value of single baseline measurements of biomarkers like N‐terminal pro‐B‐type natriuretic peptide is limited, with the BioMEMS study we advocate a dynamic, serial approach to better capture HF progression. We will substantiate this by relating repeated biomarker measurements to PA pressures. This design rationale presents a comprehensive review on cardiac biomarkers in HF, and aims to contribute valuable insights into personalized HF therapy and patient risk assessment, advancing our ability to address the evolving nature of HF effectively. Design and rationale of the BioMEMS study. QoL, quality of life. Graphical is created with BioRender.com
ISSN:1388-9842
1879-0844
1879-0844
DOI:10.1002/ejhf.3303